Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P17301

UPID:
ITA2_HUMAN

ALTERNATIVE NAMES:
CD49 antigen-like family member B; Collagen receptor; Platelet membrane glycoprotein Ia; VLA-2 subunit alpha

ALTERNATIVE UPACC:
P17301; Q14595

BACKGROUND:
Integrin alpha-2 functions as a receptor for various microbial infections, including Human rotavirus A and echoviruses 1 and 8, indicating its role in immune response. Known for its binding to collagen and other extracellular matrix components, it is essential for platelet adhesion and the organization of the extracellular matrix.

THERAPEUTIC SIGNIFICANCE:
Exploring Integrin alpha-2's interactions with pathogens offers a pathway to developing novel therapeutic approaches. Its critical function in adhesion and immune response positions it as a key target in designing treatments for infectious diseases and disorders related to extracellular matrix organization.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.